Creative Medical Technology (NASDAQ:CELZ) and Taysha Gene Therapies (NASDAQ:TSHA) Head to Head Comparison

Creative Medical Technology (NASDAQ:CELZ) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Profitability

This table compares Creative Medical Technology and Taysha Gene Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-63.05%	-60.42%
Taysha Gene Therapies	-229.67%	-106.36%	-49.16%

Earnings & Valuation

This table compares Creative Medical Technology and Taysha Gene Therapies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10,000.00	829.50	-$5.29 million	($3.80)	-1.25
Taysha Gene Therapies	$9.92 million	33.69	-$111.57 million	$0.63	2.59

Creative Medical Technology has higher earnings, but lower revenue than Taysha Gene Therapies. Creative Medical Technology is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Creative Medical Technology has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Creative Medical Technology and Taysha Gene Therapies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	0	0	0	0	0.00
Taysha Gene Therapies	0	0	8	0	3.00

Taysha Gene Therapies has a consensus target price of $6.63, indicating a potential upside of 306.44%. Given Taysha Gene Therapies’ stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Creative Medical Technology.

Institutional & Insider Ownership

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 2.8% of Creative Medical Technology shares are owned by insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Taysha Gene Therapies beats Creative Medical Technology on 8 of the 14 factors compared between the two stocks.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.